Haploinsufficiency at the Nkx3.1 locus: A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation

Cancer Cell

Volumn 3, Issue 3, 2003, Pages 273-283

  Magee, Jeffrey A ^a   Abdulkadir, Sarki A ^b   Milbrandt, Jeffrey ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN NKX3.1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; TESTOSTERONE;

ALLELE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL REGENERATION; CONTROLLED STUDY; DNA MICROARRAY; EPITHELIUM HYPERPLASIA; GENE ACTIVATION; GENE CONTROL; GENE DOSAGE; GENE FREQUENCY; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCUS; HAPLOIDY; HETEROZYGOSITY LOSS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SIGNAL TRANSDUCTION; STOCHASTIC MODEL; TUMOR SUPPRESSOR GENE; ANIMAL; BIOLOGICAL MODEL; CELL DIVISION; COMPARATIVE STUDY; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC PREDISPOSITION; GENETICS; MOUSE MUTANT; ORCHIECTOMY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALIA;

ALLELES; ANIMALS; CELL DIVISION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, MUTANT STRAINS; MODELS, BIOLOGICAL; ORCHIECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0042787650     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00047-3     Document Type: Article

References (32)

1. Abdulkadir S.A., Magee J.A., Peters T.J., Kaleem Z., Naughton C.K., Humphrey P.A., Milbrandt J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22:2002;1495-1503.
2. Abrahamsson P.A., Lilja H., Falkmer S., Wadstrom L.B. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate. 12:1988;39-46.
3. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R., et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13:1999;966-977.
4. Bieberich C.J., Fujita K., He W.W., Jay G. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J. Biol. Chem. 271:1996;31779-31782.
5. Bova G.S., Carter B.S., Bussemakers M.J., Emi M., Fujiwara Y., Kyprianou N., Jacobs S.C., Robinson J.C., Epstein J.I., Walsh P.C., et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 53:1993;3869-3873.
6. Cook W.D., McCaw B.J. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene. 19:2000;3434-3438.
7. Davidoff A.M., Humphrey P.A., Iglehart J.D., Marks J.R. Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. USA. 88:1991;5006-5010.
8. English H.F., Santen R.J., Isaacs J.T. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate. 11:1987;229-242.
9. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
10. Fero M.L., Randel E., Gurley K.E., Roberts J.M., Kemp C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 396:1998;177-180.
11. Fiering S., Whitelaw E., Martin D.I. To be or not to be active. the stochastic nature of enhancer action Bioessays. 22:2000;381-387.
12. He W.W., Sciavolino P.J., Wing J., Augustus M., Hudson P., Meissner P.S., Curtis R.T., Shell B.K., Bostwick D.G., Tindall D.J., et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 43:1997;69-77.
13. Inoue K., Zindy F., Randle D.H., Rehg J.E., Sherr C.J. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 15:2001;2934-2939.
14. Isaacs J. Control of cell proliferation and cell death in the normal and neoplasic prostate. A stem cell model Rodgers C.H., Cunha G., Grayhack J.T., Hinman F., Horton R. Benign Prostatic Hyperplasia Volume II. 1987;NIH, Bethesda, MD. 85-94.pp.
15. Johnson M.A., Hernandez I., Wei Y., Greenberg N. Isolation and characterization of mouse probasin. An androgen-regulated protein specifically expressed in the differentiated prostate Prostate. 43:2000;255-262.
16. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA. 99:2002;2884-2889.
17. Knudson A.G. Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 45:1985;1437-1443.
18. Ko M.S., Nakauchi H., Takahashi N. The dose dependence of glucocorticoid-inducible gene expression results from changes in the number of transcriptionally active templates. EMBO J. 9:1990;2835-2842.
19. Macoska J.A., Trybus T.M., Benson P.D., Sakr W.A., Grignon D.J., Wojno K.D., Pietruk T., Powell I.J. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 55:1995;5390-5395.
20. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 349:1991;254-256.
21. McDonnell T.J., Deane N., Platt F.M., Nunez G., Jaeger U., McKearn J.P., Korsmeyer S.J. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 57:1989;79-88.
22. Pietenpol J.A., Bohlander S.K., Sato Y., Papadopoulos N., Liu B., Friedman C., Trask B.J., Roberts J.M., Kinzler K.W., Rowley J.D., et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55:1995;1206-1210.
23. Quon K.C., Berns A. Haplo-insufficiency? Let me count the ways. Genes Dev. 15:2001;2917-2921.
24. Renan M.J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 7:1993;139-146.
25. Seshadri R., Kutlaca R.J., Trainor K., Matthews C., Morley A.A. Mutation rate of normal and malignant human lymphocytes. Cancer Res. 47:1987;407-409.
26. Shindler K.S., Roth K.A. Double immunofluorescent staining using two unconjugated primary antisera raised in the same species. J. Histochem. Cytochem. 44:1996;1331-1335.
27. Svaren J., Ehrig T., Abdulkadir S.A., Ehrengruber M.U., Watson M.A., Milbrandt J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J. Biol. Chem. 275:2000;38524-38531.
28. Tsurusaki T., Koji T., Sakai H., Kanetake H., Nakane P.K., Saito Y. Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate. 35:1998;109-116.
29. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA. 98:2001;5116-5121.
30. van Roon M.A., Aten J.A., van Oven C.H., Charles R., Lamers W.H. The initiation of hepatocyte-specific gene expression within embryonic hepatocytes is a stochastic event. Dev. Biol. 136:1989;508-516.
31. Venkatachalam S., Shi Y.P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild-type p53 in tumors from p53 heterozygous mice. reduction of p53 dosage can promote cancer formation EMBO J. 17:1998;4657-4667.
32. Voeller H.J., Augustus M., Madike V., Bova G.S., Carter K.C., Gelmann E.P. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57:1997;4455-4459.